TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31277301

Group type: EXPERIMENTAL
Intervention: GEE extract 1000 mg/day
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 27753794

Group type: EXPERIMENTAL
Intervention: Hepavax-Gene TF vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Engerix-B vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 0
Study: 25659228

Group type: EXPERIMENTAL
Intervention: Warning stickers for household salt containers
Number of subjects: 150

Group type: COMPARATOR
Intervention: Leaflet about the harmful effects of excessive salt intake (control)
Number of subjects: 150
Study: 23585310

Group type: EXPERIMENTAL
Intervention: No Test Atorvastatin 80 mg/day (A80)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KIF6 Testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No Test Pravastatin 40 mg/day (P40)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Test A80
Number of subjects: 0
Study: 22569014

Group type: COMPARATOR
Intervention: 1 mg of epinephrine with a nasal pack soaked in 20 mL of saline for 10 minutes before surgery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 4 mg of epinephrine with a nasal pack soaked in 20 mL of saline for 10 minutes before surgery
Number of subjects: 30
Study: 19019052

Group type: EXPERIMENTAL
Intervention: Bilateral occipital nerve blocks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional expectant therapy (adequate hydration, complete bed rest, and analgesics)
Number of subjects: 50
Study: 17710964

Group type: EXPERIMENTAL
Intervention: Pueraria mirifica, oral 50 and 100 mg capsule, once daily for six months
Number of subjects: 10
Study: 15186874

Group type: EXPERIMENTAL
Intervention: Culture-specific diabetes care intervention
Number of subjects: 101
Study: 11513444

Group type: COMPARATOR
Intervention: Active can anode
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Three-finger array lead
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Omitting the middle finger of the array lead
Number of subjects: 68

Group type: COMPARATOR
Intervention: Active can device with two-finger array lead
Number of subjects: 68
Study: 9041281

Group type: EXPERIMENTAL
Intervention: Thyrotropin-Releasing Hormone (TRH) 200 microg
Number of subjects: 1022
Study: 8261468

Group type: EXPERIMENTAL
Intervention: 125 mg furafylline
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2445932

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Mitomycin-C plus Cisplatin (MC)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: MVB plus Cisplatin (MVBC)
Number of subjects: 119
Study: 31604440

Group type: EXPERIMENTAL
Intervention: Novel personalized TKR design (Persona CR, Zimmer, Warsaw, IN, USA)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Conventional TKR design (PFC CR, DePuy, Warsaw, IN, USA)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Conventional TKR design (Nexgen CR, Zimmer, Warsaw, IN, USA)
Number of subjects: 240
Study: 29890724

Group type: EXPERIMENTAL
Intervention: Fructose 5 g
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fructose 10 g
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Allulose 5 g
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Allulose 10 g
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (0 g)
Number of subjects: 27
Study: 26883282

Group type: EXPERIMENTAL
Intervention: Phone conference call
Number of subjects: 70

Group type: COMPARATOR
Intervention: Social media platform
Number of subjects: 70
Study: 23984673

Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg/day
Number of subjects: 426

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 426
Study: 22810946

Group type: EXPERIMENTAL
Intervention: Tonopen XL measurement of IOP through low-power lotrafilcon B lenses
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Tonopen XL measurement of IOP through high-power lotrafilcon B lenses
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Tonopen XL measurement of IOP through low-power galyfilcon A lenses
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Tonopen XL measurement of IOP through high-power galyfilcon A lenses
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Tonopen XL measurement of IOP through senofilcon A lenses
Number of subjects: 78
Study: 20979671

Group type: EXPERIMENTAL
Intervention: Flutter mucus-clearance device
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (routine healthcare)
Number of subjects: 60
Study: 19018688

Group type: EXPERIMENTAL
Intervention: Manidipine 20 mg
Number of subjects: 91

Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 91
Study: 16085605

Group type: EXPERIMENTAL
Intervention: Total hip replacement
Number of subjects: 102

Group type: COMPARATOR
Intervention: Internal fixation
Number of subjects: 102
Study: 12046885

Group type: EXPERIMENTAL
Intervention: Compound ablation (Group 1)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Standard cross‐cylinder technique (Group 2)
Number of subjects: 4
Study: 10073834

Group type: EXPERIMENTAL
Intervention: Patients with ventricular tachyarrhythmias (VT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients without ventricular tachyarrhythmias (VT)
Number of subjects: 0
Study: 7741574

Group type: EXPERIMENTAL
Intervention: Spacer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nebuliser
Number of subjects: 60
Study: 2147609

Group type: EXPERIMENTAL
Intervention: Ketotifen (K)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 32
Study: 6989377

Group type: EXPERIMENTAL
Intervention: Clofibate
Number of subjects: 95

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Niceritrol
Number of subjects: 95
Study: 31965682

Group type: EXPERIMENTAL
Intervention: Subepidermal moisture (SEM) biocapacitance measurement
Number of subjects: 182

Group type: COMPARATOR
Intervention: Standard of care clinical interventions
Number of subjects: 182
Study: 31532805

Group type: EXPERIMENTAL
Intervention: Coping
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 187

Group type: COMPARATOR
Intervention: Insight, medication adherence, addiction
Number of subjects: 187
Study: 27993816

Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg/week for 1 year)
Number of subjects: 2591

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 2591

Group type: EXPERIMENTAL
Intervention: Bevacizumab with chemotherapy
Number of subjects: 2591

Group type: COMPARATOR
Intervention: Both treatment arms
Number of subjects: 2591
Study: 25761742

Group type: EXPERIMENTAL
Intervention: Baseline serum uric acid levels
Number of subjects: 93
Study: 23625191

Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best Supportive Care (BSC)
Number of subjects: 0
Study: 21276883

Group type: EXPERIMENTAL
Intervention: LPV/r (lopinavir/ritonavir) monotherapy
Number of subjects: 136

Group type: COMPARATOR
Intervention: LPV/r+ZDV+3TC (lopinavir/ritonavir with zidovudine and lamivudine)
Number of subjects: 136
Study: 19144144

Group type: EXPERIMENTAL
Intervention: Children living in households with lower economic or education levels
Number of subjects: 3354

Group type: EXPERIMENTAL
Intervention: Children living near the hydrographic network
Number of subjects: 3354

Group type: EXPERIMENTAL
Intervention: Children living in sparsely built-up areas
Number of subjects: 3354

Group type: EXPERIMENTAL
Intervention: Children living in irregularly built areas
Number of subjects: 3354

Group type: EXPERIMENTAL
Intervention: Children who did not use a bed net
Number of subjects: 3354

Group type: EXPERIMENTAL
Intervention: Children sampled during the rainy season
Number of subjects: 3354

Group type: EXPERIMENTAL
Intervention: Children who had traveled outside of Ouagadougou
Number of subjects: 3354

Group type: EXPERIMENTAL
Intervention: Overall prevalence of CSP-antibodies during dry season
Number of subjects: 3354

Group type: EXPERIMENTAL
Intervention: Overall prevalence of P. falciparum infections during dry season
Number of subjects: 3354

Group type: EXPERIMENTAL
Intervention: Overall prevalence of CSP-antibodies during rainy season
Number of subjects: 3354

Group type: EXPERIMENTAL
Intervention: Overall prevalence of P. falciparum infections during rainy season
Number of subjects: 3354
Study: 17920972

Group type: EXPERIMENTAL
Intervention: Acupressure at true points
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 32
Study: 15491083

Group type: EXPERIMENTAL
Intervention: Tooth-brushing done once a day before breakfast (phase 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Twice daily mouthrinsing with 0.2% sodium fluoride (phase 2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Twice daily mouthrinsing with 0.03% triclosan and 0.05% sodium fluoride (phase 3)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Twice daily mouthrinsing with 0.2% chlorhexidine (phase 4)
Number of subjects: 20
Study: 11296177

Group type: EXPERIMENTAL
Intervention: Mouth pressure during sniff maneuver (Pmosn)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Maximal inspiratory pressure (MIP)
Number of subjects: 30
Study: 9762666

Group type: COMPARATOR
Intervention: T cell receptor V beta 5 analysis in MS patients (8 patients)
Number of subjects: 17

Group type: COMPARATOR
Intervention: T cell receptor V beta 17 analysis in MS patients (8 patients)
Number of subjects: 17
Study: 7816001

Group type: EXPERIMENTAL
Intervention: 2 g elemental calcium/day (n = 9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 18
Study: 2454615

Group type: EXPERIMENTAL
Intervention: CAPM (cyclophosphamide, adriamycin, cisplatin, mitomycin C)
Number of subjects: 167

Group type: COMPARATOR
Intervention: MCT (mitomycin C, cytosine arabinoside, tegafur)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: PAP (cisplatin, adriamycin, peplomycin)
Number of subjects: 167

Group type: COMPARATOR
Intervention: MCTTT (mitomycin C, cyclophosphamide, tespamine, toyomycin, tegafur)
Number of subjects: 167
Study: 31713464

Group type: EXPERIMENTAL
Intervention: PEER intervention
Number of subjects: 41

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 41
Study: 30419966

Group type: EXPERIMENTAL
Intervention: Transcutaneous stimulation at 10 kHz
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Transcutaneous stimulation at 5 kHz
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 11
Study: 28586588

Group type: EXPERIMENTAL
Intervention: Epidural injection of bupivacaine plus methylprednisolone
Number of subjects: 109

Group type: COMPARATOR
Intervention: Epidural injection of bupivacaine only
Number of subjects: 109
Study: 24703286

Group type: EXPERIMENTAL
Intervention: Self-tapping miniscrews (35 patients, 70 screws)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Self-drilling miniscrews (35 patients, 70 screws)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Self-drilling miniscrews with root contact
Number of subjects: 70

Group type: COMPARATOR
Intervention: Self-tapping miniscrews with no root contact
Number of subjects: 70
Study: 22653618

Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation with a telehealth monitoring device for four months
Number of subjects: 111

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 111
Study: 20363901

Group type: EXPERIMENTAL
Intervention: Think framing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feel framing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive orientation priming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Affective orientation priming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Processing fluency mediation
Number of subjects: 0
Study: 18841082

Group type: EXPERIMENTAL
Intervention: 15-second rest interval
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 30-second rest interval
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 60-second rest interval
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 30-second rest interval for older women
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1:1 exercise-to-rest ratio for knee flexor recovery in older women
Number of subjects: 36
Study: 15513491

Group type: EXPERIMENTAL
Intervention: WizAir-DVT device
Number of subjects: 50

Group type: COMPARATOR
Intervention: Kendall SCD
Number of subjects: 50
Study: 11229421

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (non-diabetic women)
Number of subjects: 32
Study: 9505748

Group type: EXPERIMENTAL
Intervention: Propofol + lignocaine 0.1 mg.kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol + lignocaine 0.2 mg.kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cold propofol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol premixed with normal saline (control group)
Number of subjects: 0
Study: 8002056

Group type: EXPERIMENTAL
Intervention: Megaloblastic anemia patients
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Megaloblastic anemia patients after correction of anemia
Number of subjects: 31
Study: 3292250

Group type: EXPERIMENTAL
Intervention: Taurine-supplemented formula (480 mumol/l)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cow's milk formula without taurine
Number of subjects: 20
Study: 29681228

Group type: EXPERIMENTAL
Intervention: Driving
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Exercise plus driving
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 28838846

Group type: EXPERIMENTAL
Intervention: Coronary CT angiography (CTA)
Number of subjects: 9470

Group type: COMPARATOR
Intervention: Functional testing (nuclear stress testing)
Number of subjects: 9470
Study: 25386668

Group type: EXPERIMENTAL
Intervention: Oral CoQ10 (200 mg/day) plus NADH (20 mg/day) supplementation
Number of subjects: 73
Study: 23333369

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 34713

Group type: EXPERIMENTAL
Intervention: Body weight
Number of subjects: 34713

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 34713

Group type: EXPERIMENTAL
Intervention: Height
Number of subjects: 34713
Study: 21395643

Group type: EXPERIMENTAL
Intervention: Hydrofluoroalkane formulation of budesonide (800 µg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorofluorocarbon formulation of budesonide (800 µg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrofluoroalkane formulation of budesonide (200 µg followed by 800 µg for 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorofluorocarbon formulation of budesonide (200 µg followed by 800 µg for 4 weeks)
Number of subjects: 0
Study: 18693327

Group type: EXPERIMENTAL
Intervention: Per cycle analysis of treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total number of randomized women analysis
Number of subjects: 0
Study: 16492275

Group type: EXPERIMENTAL
Intervention: Drain inserted during forearm closing (Group I, n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No drain used (Group II, n = 40)
Number of subjects: 80
Study: 12582975

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: COMPARATOR
Intervention: Clonazepam vs. Placebo
Number of subjects: 27
Study: 10852601

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) in combination with cyclosporine (CsA) and prednisone (Pred)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Cyclosporine (CsA) and prednisone (Pred)
Number of subjects: 184
Study: 9085014

Group type: EXPERIMENTAL
Intervention: Bronchial hyperresponsiveness defined as the provocative dose causing a 20% fall in FEV1
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Bronchial hyperresponsiveness defined as a 10% fall in FEV1
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Bronchial hyperresponsiveness defined using corresponding cut‐off values of the linear dose‐response slopes of the percent decline in FEV1 (DRS)
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Multiple linear regression analyses of various transformations of the DRS
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Reciprocally transformed DRS
Number of subjects: 931
Study: 8449396

Group type: EXPERIMENTAL
Intervention: 1% Halon 1301 (bromotrifluoromethane, CBrF3)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 8
Study: 3953986

Group type: EXPERIMENTAL
Intervention: 0.08% bupivacaine (Group A)
Number of subjects: 53

Group type: COMPARATOR
Intervention: 0.25% bupivacaine (Group B)
Number of subjects: 53
Study: 31332835

Group type: EXPERIMENTAL
Intervention: Block bone substitute (DBBM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Particulate bone substitute (DBBM)
Number of subjects: 24
Study: 30239757

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25970741

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention or metformin
Number of subjects: 1816
Study: 25443696

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 1619

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1619

Group type: EXPERIMENTAL
Intervention: Exercise treatment
Number of subjects: 1619
Study: 22678095

Group type: EXPERIMENTAL
Intervention: MiniYAG (small low-energy Nd:YAG capsulotomy)
Number of subjects: 25

Group type: COMPARATOR
Intervention: GentleYAG (low-energy Nd:YAG laser treatment without opening the lens capsule)
Number of subjects: 25
Study: 20032276

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 387
Study: 18783071

Group type: EXPERIMENTAL
Intervention: Surgical sphincterotomy
Number of subjects: 70

Group type: COMPARATOR
Intervention: 0.2% glyceryl trinitrate ointment
Number of subjects: 70
Study: 15087961

Group type: EXPERIMENTAL
Intervention: Morphine patient‐controlled analgesia with presurgical bupivacaine sciatic nerve blockade
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Morphine patient‐controlled analgesia with postsurgical bupivacaine sciatic nerve blockade
Number of subjects: 30

Group type: COMPARATOR
Intervention: Morphine patient‐controlled analgesia alone
Number of subjects: 30
Study: 11033402

Group type: EXPERIMENTAL
Intervention: Peribulbar anesthesia
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Retrobulbar anesthesia
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 16
Study: 9323470

Group type: EXPERIMENTAL
Intervention: Neutropenic bacteremic patients
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Bacteremic patients
Number of subjects: 123

Group type: COMPARATOR
Intervention: Non-bacteremic patients
Number of subjects: 123
Study: 8418020

Group type: EXPERIMENTAL
Intervention: maxEPA 20 g/day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: maxEPA 10 g/day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: maxEPA 5 g/day
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo 20 g/day
Number of subjects: 9
Study: 3535967

Group type: EXPERIMENTAL
Intervention: Tinidazole single perioperative prophylactic dose of 2 g
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tinidazole treatment course of 8 g over 7 days
Number of subjects: 20
Study: 30503704

Group type: EXPERIMENTAL
Intervention: Caregiver relief after the death of a family member with dementia (FaCTS)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Preparedness for care recipient's (CR's) death
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Perception of CR's death as a relief
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Greater CG relief
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: CG relief
Number of subjects: 312
Study: 29058596

Group type: EXPERIMENTAL
Intervention: Inhaled Hydrogen (2% hydrogen with 24% to 50% oxygen) for 18 hours after admission via mechanical ventilation
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group (24% to 50% oxygen) for 18 hours after admission via mechanical ventilation
Number of subjects: 360
Study: 25619692

Group type: EXPERIMENTAL
Intervention: Surgical treatment with open reduction and internal fixation (ORIF)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 76
Study: 23324076

Group type: EXPERIMENTAL
Intervention: Survival processing scenario
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moving to a new house
Number of subjects: 0
Study: 22935858

Group type: EXPERIMENTAL
Intervention: Mature mud pack
Number of subjects: 27

Group type: COMPARATOR
Intervention: Hot pack
Number of subjects: 27
Study: 18926614

Group type: EXPERIMENTAL
Intervention: Prime & Bond NT Dual Cure + Calibra (non-thermocycled)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: OptiBond All-in-One Dual Cure + Nexus 2 (non-thermocycled)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Xeno IV Dual Cure + Calibra (thermocycled)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: OptiBond Solo Plus Dual Cure + Nexus 2 (non-thermocycled)
Number of subjects: 160
Study: 17971007

Group type: EXPERIMENTAL
Intervention: Aquacel dressing (moist wound healing)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Mepore dressing (standard care)
Number of subjects: 160
Study: 14999522

Group type: EXPERIMENTAL
Intervention: 5 mg risedronate administered in the morning under fasting condition without breakfast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 mg risedronate administered 30 min before breakfast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 mg risedronate administered 30 min after breakfast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 mg risedronate administered 3 h after breakfast
Number of subjects: 0
Study: 11153450

Group type: EXPERIMENTAL
Intervention: Radical multiple synovectomy (RaMS) with continued pre-operative medication (group A)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Combination therapy with DMARDs after RaMS (group B)
Number of subjects: 67

Group type: COMPARATOR
Intervention: No surgery, combination therapy with DMARDs (group C - control)
Number of subjects: 67